seri
doubli
flexibl
nucleosid
analogu
design
base
acycl
sugar
scaffold
acyclovir
flexbas
moieti
found
flexim
target
compound
evalu
antivir
potenti
found
inhibit
sever
coronavirus
significantli
compound
display
select
antivir
activ
cc
ec
toward
human
coronaviru
hcov
middl
east
respiratori
syndromecoronaviru
sever
acut
respiratori
syndromecoronaviru
case
activ
highli
promis
ec
cc
doubli
flexibl
nucleosid
analogu
view
novel
new
class
drug
candid
potenti
potent
inhibit
coronavirus
current
approv
treatment
vaccin
human
coronavirus
hcov
potenti
lethal
zoonot
cov
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
current
mer
outbreak
ongo
almost
three
year
well
thousand
confirm
case
document
mortal
rate
sinc
sar
outbreak
extens
effort
target
coronaviru
famili
includ
screen
librari
alreadi
approv
antivir
drug
acyclovir
acv
ganciclovir
lamivudin
zidovudin
unfortun
none
well
known
antivir
drug
exhibit
activ
sarscov
merscov
vitro
sarscov
screen
effort
howev
yield
small
number
lead
includ
nucleosid
analogu
ribavirin
guanosinelik
analogu
exhibit
broadspectrum
antivir
activ
ribavirin
found
inhibit
coronaviru
replic
vitro
inhibitori
concentr
much
higher
need
inhibit
virus
consequ
appear
repres
viabl
treatment
option
moreov
recent
studi
suggest
case
coronavirus
ribavirin
antivir
activ
primarili
due
lethal
mutagenesi
rather
effect
cell
gtp
biosynthesi
beyond
studi
report
novel
nucleosid
inhibitor
studi
develop
combat
coronaviru
infect
hcov
first
identifi
two
speci
known
time
virus
known
caus
larg
number
common
cold
typic
mild
symptom
except
suffer
ill
particularli
immunocompromis
system
new
coronaviru
pathogen
associ
sever
lung
diseas
emerg
guangzhou
later
spread
southern
china
hong
kong
new
viru
name
sarscov
end
outbreak
case
confirm
sever
countri
result
fatal
sinc
two
addit
coronavirus
discov
human
recent
merscov
identifi
second
zoonot
coronaviru
caus
lethal
respiratori
infect
human
laboratori
spent
number
year
develop
differ
seri
flexibl
split
purin
base
analogu
uniqu
nucleosid
analogu
term
flexim
design
explor
nucleobas
flexibl
affect
recognit
bind
activ
nucleosid
tide
analogu
flexim
possess
purin
base
scaffold
imidazol
pyrimidin
moieti
attach
singl
carboncarbon
bond
rather
fuse
typic
purin
figur
analogu
design
retain
requisit
purin
hydrogen
bond
pattern
allow
nucleobas
explor
altern
bind
mode
previou
report
group
shown
analogu
sever
strateg
advantag
increas
bind
affin
compar
correspond
rigid
inhibitor
bind
affin
atyp
enzym
well
abil
overcom
point
mutat
biolog
signific
bind
site
design
target
molecul
flexbas
modif
flexim
combin
acycl
sugar
moieti
acyclovir
acv
acv
nucleosid
polymeras
inhibitor
current
approv
treatment
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
infect
recent
also
found
activ
human
immunodefici
viru
hiv
mcguigan
protid
technolog
employ
found
suppress
replic
submicromolar
rang
lymphoid
cervicovagin
human
tissu
cell
analogu
design
hope
mimick
broadspectrum
biolog
activ
approach
synthesi
analogu
began
previous
publish
rout
acycl
sugar
moieti
util
seri
organometal
coupl
techniqu
order
construct
flexibl
base
rout
involv
coupl
acetoxymethyleth
synthes
accord
publish
procedur
diiodoimidazol
use
modifi
vorbruggen
condit
follow
remov
labil
acet
protect
group
subsequ
protect
robust
benzyl
select
deiodin
etmgbr
scheme
yield
key
intermedi
product
serv
key
intermedi
seri
organometal
coupl
reaction
first
coupl
partner
select
boron
acid
deriv
analogu
chosen
due
versatil
compound
previous
publish
group
hypothes
would
possibl
obtain
flexxanthosin
flexguanosin
analogu
scheme
prepar
boron
acid
follow
establish
procedur
use
immedi
without
character
use
standard
suzuki
reaction
condit
presenc
freshli
prepar
pd
pph
obtain
yield
order
obtain
xanthosin
analogu
treat
pdc
remov
benzyl
protect
group
yield
final
compound
yield
also
discov
lower
temperatur
reaction
benzyl
group
could
select
remov
base
conveni
would
allow
futur
function
without
need
select
reprotect
free
hydroxyl
attempt
obtain
guanosin
analogu
treat
methanol
ammonia
pressur
yield
intermedi
diamino
compound
unfortun
reaction
result
singl
site
transform
due
extrem
reaction
condit
low
yield
rout
abandon
ultim
guanosin
analogu
obtain
still
coupl
key
intermedi
appropri
pyrimidin
pyrimidin
prepar
commerci
avail
pyrimidin
accord
publish
procedur
subsequ
coupl
complet
use
modifi
still
coupl
condit
base
find
mee
et
al
order
acquir
final
compound
select
deprotect
use
remov
benzyl
group
leav
intact
done
pdc
presenc
ammonium
format
etoh
reflux
hour
yield
yield
remaind
retriev
start
materi
could
recycl
final
deprotect
accomplish
bbr
room
temperatur
yield
yield
first
screen
effect
three
target
flexim
analogu
replic
evalu
infect
result
full
cytopathi
cell
cultur
model
use
reason
antivir
effect
analyz
microscop
score
virusinduc
cytopathogen
effect
cpe
well
scale
mild
sever
score
use
calcul
percentag
inhibit
normal
control
well
shown
tabl
contrast
acyclovir
one
test
nucleosid
nucleosid
demonstr
select
antivir
activ
cc
ec
base
result
also
evalu
activ
nucleosid
pathogen
virus
merscov
sarscov
infect
vero
cell
merscov
cell
sarscov
result
complet
cpe
allow
quantif
antivir
effect
use
commerci
cell
viabil
assay
describ
previous
inhibit
virusinduc
cpe
ie
enhanc
cell
viabil
compar
untreat
virusinfect
cell
determin
presenc
differ
compound
concentr
result
depict
tabl
indic
compound
block
replic
merscov
sarscov
acyclovir
effect
tabl
effect
signific
ec
cc
experi
show
reduc
viabil
differ
cell
line
differ
concentr
suggest
cellspecif
effect
differ
sensit
cell
line
toward
nucleosid
could
caus
differ
growth
rate
compound
uptak
metabol
cell
linespecif
characterist
need
new
effect
antivir
therapeut
particularli
target
emerg
reemerg
infecti
diseas
pathogen
continu
increas
herein
describ
design
synthesi
preliminari
screen
seri
novel
nucleosid
analogu
employ
strategi
combin
flexbas
motif
flexibl
acycl
sugar
scaffold
fdaapprov
drug
acyclovir
shown
approach
produc
medicin
relev
molecul
capabl
inhibit
merscov
replic
cell
cultur
although
parent
compound
acyclovir
serv
polymeras
inhibitor
yet
unclear
novel
analogu
disrupt
viral
replic
effort
underway
pursu
addit
analogu
use
elucid
mechan
action
moreov
comparison
activ
profil
compound
draw
specul
methoxi
group
may
serv
prodrug
establish
antivir
nucleosid
analogu
thu
addit
prodrug
moieti
pursu
subsequ
studi
approach
shown
greatli
enhanc
antivir
activ
nucleosid
analogu
conclus
aid
us
effort
effect
design
second
gener
analogu
addit
function
pursu
order
explor
analogu
potenti
antivir
agent
result
studi
report
elsewher
becom
avail
